On Thursday The Drug Enforcement Administration announced that it would reject petitions to reschedule marijuana as a Schedule II drug or lower. As a Schedule I drug, marijuana use is strictly prohibited outside of research. A Schedule II classification would have allowed its usage as a federally-approved prescription medical therapy.The rejection, according to a Federal Register notice, was based on an analysis by the Food and Drug Administration and recommendations from the Department of Health and Human Services.
The notice from the DEA stated the following three reasons why marijuana would not be rescheduled. Stating the potential for and history of abuse and addiction, lack of accepted medical use, and a lack of safety information. The last two reasons are part of the drug’s failure of a five-part FDA test that states that for a medicinal drug “the drug’s chemistry must be known and reproducible,” “there must be adequate safety studies,” “there must be adequate and well-controlled studies proving efficacy,” “the drug must be accepted by qualified experts,” and “the scientific evidence must be widely available.” The clinical data that could even meet the FDA’s review standards was subject to intense scrutiny. In the end, the FDA could only find 11 research articles that met its review qualifications of being randomized, double-blind, placebo-controlled clinical studies.
This decision by the DEA still keeps over 40 states and the District of Columbia that allow some form of medical marijuana usage in technical noncompliance with federal law. The decision itself also inhibits legitimate clinical research that could remedy the FDA’s lack of data. While the DEA has approved a recent study of medical marijuana in treating veterans with post-traumatic stress disorders and in 2015 relaxed its requirements for medical testing on cannabidiol marijuana extracts, the process for determining medical efficacy is complicated and difficult.
However, what we found is very contradicting as the United States of America has a U.S. Patent on Cannabinoids stating that it is an antioxidant and a neuroprotectant which was filed on April 21, 1999, and that it is useful for treating many ailments such as Alzheimer’s disease, Parkinson’s disease, and HIV dementia.
Read below to read more on the US Patent and share this article with your friends. Remember let’s think higher and knowledge is power.
United States Patent 6630507
To stay updated on the latest tech, entrepreneurs and innovative companies in the cannabis industry, click here.